<?xml version="1.0" encoding="UTF-8" ?>
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study</dc:title>
<dc:creator>Ríos-Tamayo, Rafael</dc:creator>
<dc:creator>Soler, Juan Alfons</dc:creator>
<dc:creator>García-Sánchez, Ricarda</dc:creator>
<dc:creator>Pérez Persona, Ernesto</dc:creator>
<dc:creator>Arnao, Mario</dc:creator>
<dc:creator>García-Guiñón, Antoni</dc:creator>
<dc:creator>Domingo, Abel</dc:creator>
<dc:creator>González-Pardo, Miriam</dc:creator>
<dc:creator>de la Rubia Comos, Javier</dc:creator>
<dc:creator>Mateos, Maria-Victoria</dc:creator>
<dc:creator>GeminiS Study Investigators</dc:creator>
<dc:subject>Relapsed-refractory multiple myeloma</dc:subject>
<dc:subject>Real-world</dc:subject>
<dc:subject>Monoclonal antibodies</dc:subject>
<dc:subject>Daratumumab</dc:subject>
<dc:subject>Standard of care</dc:subject>
<dc:subject>32 Ciencias Médicas</dc:subject>
<dc:description>The aim of this study is to describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.</dc:description>
<dc:description>This study was sponsored by Janssen-Cilag. Janssen-Cilag participated in the study design, data analysis and drafting of the manuscript. All investigators received financial com- pensation for their participation in the study.</dc:description>
<dc:description>Medicina</dc:description>
<dc:date>2024-06-25T11:40:20Z</dc:date>
<dc:date>2024-06-25T11:40:20Z</dc:date>
<dc:date>2023-02</dc:date>
<dc:type>article</dc:type>
<dc:identifier>http://hdl.handle.net/20.500.12466/4403</dc:identifier>
<dc:identifier>10.1080/16078454.2023.2178997</dc:identifier>
<dc:identifier>1607-8454</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>openAccess</dc:rights>
</oai_dc:dc>
<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">
<edm:ProvidedCHO about="http://hdl.handle.net/20.500.12466/4403">
<dc:creator>Ríos-Tamayo, Rafael</dc:creator>
<dc:creator>Soler, Juan Alfons</dc:creator>
<dc:creator>García-Sánchez, Ricarda</dc:creator>
<dc:creator>Pérez Persona, Ernesto</dc:creator>
<dc:creator>Arnao, Mario</dc:creator>
<dc:creator>García-Guiñón, Antoni</dc:creator>
<dc:creator>Domingo, Abel</dc:creator>
<dc:creator>González-Pardo, Miriam</dc:creator>
<dc:creator>de la Rubia Comos, Javier</dc:creator>
<dc:creator>Mateos, Maria-Victoria</dc:creator>
<dc:creator>GeminiS Study Investigators</dc:creator>
<dc:date>2023-02</dc:date>
<dc:description>The aim of this study is to describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives.</dc:description>
<dc:identifier>http://hdl.handle.net/20.500.12466/4403</dc:identifier>
<dc:language>eng</dc:language>
<dc:subject>Relapsed-refractory multiple myeloma</dc:subject>
<dc:subject>Real-world</dc:subject>
<dc:subject>Monoclonal antibodies</dc:subject>
<dc:subject>Daratumumab</dc:subject>
<dc:subject>Standard of care</dc:subject>
<dc:subject>32 Ciencias Médicas</dc:subject>
<dc:title>A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study</dc:title>
<dc:type>article</dc:type>
<edm:type>TEXT</edm:type>
</edm:ProvidedCHO>
<ore:Aggregation about="http://hdl.handle.net/20.500.12466/4403#aggregation">
<edm:dataProvider>Repositorio Institucional de la Universidad Católica de Valencia San Vicente Mártir</edm:dataProvider>
<edm:provider>Hispana</edm:provider>
</ore:Aggregation>
<edm:WebResource about="https://riucv.ucv.es/bitstream/20.500.12466/4403/1/A%20glimpse%20into%20relapsed%20refractory%20multiple%20myeloma%20treatment%20in%20real-world%20practice%20in%20Spain%20the%20GeminiS%20study.pdf">
</edm:WebResource>
</rdf:RDF>